Ratings HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Market Closed - London S.E. Other stock markets 11:35:00 2024-06-06 am EDT			5-day change	1st Jan Change
290 ^GBX	-0.34%		-2.68%	+2.47%

Jun. 03	HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine	CI
May. 24	HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's enterprise value to sales, at 3.23 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HUTCHMED (CHINA) LIMITED	+2.47%	3.17B	C+
ELI LILLY AND COMPANY	+43.64%	749B	C+
NOVO NORDISK A/S	+39.42%	605B	B
JOHNSON & JOHNSON	-6.58%	351B	C+
MERCK & CO., INC.	+19.72%	328B	B-
ABBVIE INC.	+8.78%	292B	C+
NOVARTIS AG	+11.92%	216B	B-
ROCHE HOLDING AG	-2.62%	214B	A+
PFIZER, INC.	+0.03%	167B	C+
AMGEN INC.	+6.13%	165B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes